Marco milano (Talk | contribs) |
Marco milano (Talk | contribs) |
||
Line 15: | Line 15: | ||
<div class="pt-lg-lg pb-lg-sm text-center text-lg-left"> | <div class="pt-lg-lg pb-lg-sm text-center text-lg-left"> | ||
<h2 class="h1 text-white mb-3">CAPOEIRA</h2> | <h2 class="h1 text-white mb-3">CAPOEIRA</h2> | ||
− | <p class="lead text-white lh-180"> | + | <p class="lead text-white lh-180">CAncer PersOnalized Encapsulin Immunotherapy and Relapse Assay</p> |
<a href="#CAP" class="btn btn-white btn-circle btn-translate--hover btn-icon mr-sm-4 scroll-me"> | <a href="#CAP" class="btn btn-white btn-circle btn-translate--hover btn-icon mr-sm-4 scroll-me"> |
Revision as of 22:41, 17 October 2018
CAPOEIRA
CAncer PersOnalized Encapsulin Immunotherapy and Relapse Assay
Learn more about our projectWhat is CAPOEIRA ?
While Melanoma remains the deadliest form of skin cancer, immunotherapy approaches can harness our immune system to defeat it! Yet, current immuno-treatments suffer from high costs, limited accessibility, and poor specificity. Our project “CAPOEIRA”, named after the Brazilian self-defense martial-art, exploits the potential of synthetic biology to develop a personalized, cost-effective, and rapid production scheme for cancer vaccine and point-of-care relapse surveillance. First, a bioinformatic pipeline integrating state-of-the-art tools identifies our targets: melanoma neoantigens, the fingerprints of cancer cells. Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes. This encapsulin vaccine activates dendritic cells which trigger T-cells’ attack on the neoantigen-bearing cancer cells. Nevertheless, we don’t underestimate a defeated villain! To detect potential relapse, we combine techniques including dumbbell probes, rolling circle amplification, isothermal amplification, and CRISPR-Cas12a to detect circulating tumor miRNA and DNA. Ultimately, CAPOEIRA trains the immune system to fight back!
This is CAPOEIRA
Bioinformatics
First, a bioinformatic pipeline integrating state-of-the-art tools identifies our target: melonoma neoantigens, the fingerprints of cancer cells
Vaccine
Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes
Dendritic cell Activation
This encapsulin vaccine activates dendritic cells which trigger T-cell's attack on the neoantigen bearing cancer cells
Follow-up
Nevertheless, we don't underestimate a defeated villain! To detect potential relapse we use techniques like CRISPR-Cas12a to detect circulationg tumor miRNA and DNA